Company intelligence / Profile preview
Biovest
Minneapolis, Minnesota, United Statescellculturecompany.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Biovest developed BiovaxID, a patient-specific active immunotherapy (therapeutic cancer vaccine) for follicular non-Hodgkin's lymphoma. BiovaxID showed evidence for prolonged remission and immune response correlation in three clinical trials (including Phase 3), but was denied marketing authorization in the EU and the company’s stock was delisted in 2017 after bankruptcy proceedings[2][1][4][5].
- Therapeutic areas
- Oncology
- Modalities
- VaccineBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
National Cancer Institute
Beyond the preview
Go deeper on Biovest.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biovest.